Literature DB >> 7189150

Nicotine antibodies: comparison of ligand specificities of antibodies produced against two nicotine conjugates.

A Castro, N Monji, H Ali, J M Yi, E R Bowman, H McKennis.   

Abstract

Conjugates between bovine serum albumin and (R,S)-2-aminonicotine were produced, and these conjugates were employed in rabbits and goats for the production of nicotine antibodies. In the assay of nicotine, an 125I-tyrosine methyl ester derivative of (R,S)-6-aminonicotine was employed as radioligand. The antibody-bound derivative was separated from the free derivative by charcoal adsorption (0.5% charcoal, 0.1% dextran T-70, 0.1% bovine serum albumin pH 7.3). Among the twenty five nicotine derivatives and metabolites examined, (R,S)-6-aminonicotine gave the highest cross-reaction. Cross-reaction with cotinine, a major mammalian metabolite of nicotine, was less than 0.1% for both the rabbit-derived and goat-derived antisera. Cross-reaction by other metabolites, such as (S)-nicotine-N'-oxide, (S)-nornicotine, and N-methylpyrrolidine was less than 1%. The antibodies produced were thus highly specific to nicotine. The radioimmunoassay for nicotine showed a maximum sensitivity of 10 ng/ml in 50-microliter plasma samples for both antisera. After the smoking of a single cigarette (1.2 mg nicotine content in mainstream) the peak of blood plasma level of nicotine in the subjects varied from 20--104 ng/ml, and high levels of nicotine were not necessarily found in heavy smokers.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7189150     DOI: 10.1111/j.1432-1033.1980.tb04433.x

Source DB:  PubMed          Journal:  Eur J Biochem        ISSN: 0014-2956


  4 in total

Review 1.  Vaccines against drugs of abuse: where are we now?

Authors:  Berma Kinsey
Journal:  Ther Adv Vaccines       Date:  2014-07

2.  Enhanced immunogenicity of a bivalent nicotine vaccine.

Authors:  D E Keyler; S A Roiko; C A Earley; M P Murtaugh; P R Pentel
Journal:  Int Immunopharmacol       Date:  2008-07-24       Impact factor: 4.932

3.  Metabolism of S-nicotine in noninduced and aroclor-induced rats.

Authors:  G Schepers; K Rustemeier; R A Walk; U Hackenberg
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1993 Apr-Jun       Impact factor: 2.441

Review 4.  Nicotine vaccines to assist with smoking cessation: current status of research.

Authors:  Tobias Raupach; Philippe H J Hoogsteder; Constant P Onno van Schayck
Journal:  Drugs       Date:  2012-03-05       Impact factor: 9.546

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.